AstraZeneca Pharma India Limited, a subsidiary of the global biopharmaceutical giant AstraZeneca, is headquartered in India and operates extensively across the country. Founded in 1979, the company has established itself as a key player in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to research and development, AstraZeneca India has introduced a range of unique products that address unmet medical needs, enhancing patient outcomes. The company is recognised for its strong market position, driven by a robust pipeline and strategic partnerships. Notable achievements include significant contributions to the healthcare landscape in India, underscoring its role in advancing medical science and improving public health.
How does AstraZeneca Pharma India Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
AstraZeneca Pharma India Limited's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, AstraZeneca Pharma India Limited reported carbon emissions of approximately 452,000 kg CO2e, a reduction from about 618,000 kg CO2e in 2023. These emissions are classified under Scope 1, which includes direct emissions from owned or controlled sources. Despite the significant reduction in emissions, AstraZeneca has not disclosed any specific reduction targets or initiatives related to the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on its operational emissions, but further details on broader climate commitments or Scope 2 and Scope 3 emissions are not available. Overall, AstraZeneca Pharma India Limited is making strides in reducing its direct carbon footprint, aligning with industry standards for climate action.
Access structured emissions data, company-specific emission factors, and source documents
2023 | 2024 | |
---|---|---|
Scope 1 | 618,000 | 000,000 |
Scope 2 | - | - |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AstraZeneca Pharma India Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.